Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Unigene Laboratories has signed a development services and clinical supply deal with the UK drug maker GlaxoSmithKline (GSK).
Subscribe to our email newsletter
As per the terms of the agreement, GSK will pay $2.2m as milestones to Unigene for the development and manufacturing activities.
These activities are connected to the active pharmaceutical ingredient and finished drug product for an oral formulation of a recombinantly produced experimental parathyroid hormone (PTH) analog to treat osteoporosis in postmenopausal women in advance of GSK’s potential decision to study the molecule in a Phase 3 program.
Unigene is developing its experimental oral PTH in collaboration with GSK, as part of an exclusive worldwide licensing agreement.
Unigene president and CEO Ashleigh Palmer they are highly focused on advancing their oral PTH that they believe has the potential to address such an important medical need.